Glunova Biotech LLC

For Research Use Only. Not for human or veterinary use. All information below is intended for qualified research professionals at accredited institutions.

TL;DR

• NAD+ (nicotinamide adenine dinucleotide) is a central coenzyme in cellular redox chemistry and a required substrate for sirtuins (SIRT1–7), PARPs, and CD38 — enzyme classes central to gene regulation, DNA repair signaling, and calcium homeostasis research.
• NAD+ depletion is documented in aging and metabolic stress model systems; supplementation studies in cell culture and animal models have examined effects on sirtuin activity, mitochondrial biogenesis, and DNA damage response.
• Glunova Biotech supplies NAD+ at ≥99% HPLC purity in 1000mg × 10 vial format for research use by qualified institutions.

Few coenzymes occupy as central a position in cellular biochemistry as nicotinamide adenine dinucleotide (NAD+). Originally characterized as an electron carrier in metabolic oxidation-reduction reactions, NAD+ has been recognized over the past two decades as a substrate for a diverse family of regulatory enzymes — including sirtuins, poly(ADP-ribose) polymerases (PARPs), and NAD+ hydrolases — that link cellular energy status to gene expression, genome integrity, and inter-cellular signaling. This overview provides research professionals with a comprehensive reference to NAD+ biology as it relates to preclinical laboratory research applications.

NAD+ Structure and Biochemistry

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a dinucleotide composed of two nucleotides — nicotinamide mononucleotide (NMN) and adenosine monophosphate (AMP) — joined by a phosphoanhydride bond. Its molecular formula is C₂₁H₂₇N₇O₁₄P₂, with a molecular weight of 663.43 Da.

The nicotinamide ring is the redox-active component: NAD+ is reduced to NADH by accepting a hydride ion (H⁻) during substrate oxidation, and NADH is re-oxidized to NAD+ by the mitochondrial electron transport chain (principally at Complex I, NADH:ubiquinone oxidoreductase). This NAD+/NADH redox couple is the primary electron carrier for:

• Glycolysis — GAPDH (glyceraldehyde-3-phosphate dehydrogenase) oxidizes glyceraldehyde-3-phosphate, reducing NAD+ to NADH
• Pyruvate decarboxylation — Pyruvate dehydrogenase complex reduces NAD+ to NADH
• TCA cycle — Isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and malate dehydrogenase each produce NADH from NAD+
• Fatty acid β-oxidation — Each cycle produces one NADH via L-3-hydroxyacyl-CoA dehydrogenase

The mitochondrial electron transport chain re-oxidizes NADH at Complex I, driving proton translocation and ATP synthesis via Complex V (ATP synthase). The NAD+/NADH ratio is thus a direct readout of cellular metabolic state and is increasingly studied as a regulatory signal in its own right.

NAD+ as a Sirtuin Substrate

Sirtuins (SIRT1–7 in mammals) are NAD+-dependent protein deacylases that catalyze the transfer of acyl groups from lysine residues on substrate proteins to the ADP-ribose moiety of NAD+, consuming one molecule of NAD+ per deacylation event. This strict NAD+ dependency couples sirtuin activity directly to cellular NAD+ availability and thus to metabolic status.

SIRT1 (nuclear/cytoplasmic): The most extensively studied sirtuin, SIRT1 deacetylates histone H3K9Ac, H4K16Ac, and numerous non-histone substrates including p53, NF-κB, PGC-1α, FOXO family transcription factors, and HIF-1α. Research has documented SIRT1’s role in transcriptional regulation of metabolic adaptation genes, inflammatory response modulation, and cellular stress resistance. In the context of NAD+ biology, SIRT1 is the primary sirtuin studied in caloric restriction models, where elevated NAD+/NADH ratios are proposed to activate SIRT1 and downstream gene regulatory programs.

SIRT3 (mitochondrial): SIRT3 is the primary mitochondrial matrix deacetylase, targeting Complex I, II, and III subunits, the acetyl-CoA synthetase AceCS2, SOD2 (MnSOD), and IDH2 for deacetylation. Published research has shown that SIRT3 activity — and thus mitochondrial protein acetylation status — is sensitive to NAD+ availability in the mitochondrial compartment. NAD+ supplementation studies have examined SIRT3 activation as a mechanism for restoring mitochondrial enzyme activity in aging model systems.

SIRT1/SIRT3 and mitochondrial biogenesis: A well-studied axis in NAD+ research involves SIRT1 deacetylation and activation of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. Activated PGC-1α drives expression of nuclear-encoded mitochondrial genes, NRF1/NRF2-dependent mitochondrial transcription factor A (TFAM) expression, and mtDNA replication. This SIRT1→PGC-1α→mitochondrial biogenesis axis is central to understanding how NAD+ levels influence mitochondrial mass and function in research models of aging, exercise adaptation, and metabolic disease.

SIRT6 (nuclear): SIRT6 has documented roles in DNA double-strand break repair (deacetylation of H3K56Ac at DNA damage sites), telomere maintenance, and metabolic regulation. SIRT6 activity is NAD+-dependent, linking genome integrity maintenance to cellular NAD+ status — a connection studied in DNA damage response and aging research.

NAD+ as a PARP Substrate

Poly(ADP-ribose) polymerases (PARPs, primarily PARP1 and PARP2) are nuclear enzymes activated by DNA strand breaks. Activated PARP1 catalyzes the ADP-ribosylation of itself and other nuclear proteins using NAD+ as the ADP-ribose donor, producing poly(ADP-ribose) (PAR) chains and releasing nicotinamide. Each ADP-ribosylation event consumes one NAD+ molecule.

In contexts of severe DNA damage, PARP1 hyperactivation can consume large quantities of NAD+, depleting cellular NAD+ pools within minutes — a process studied in models of genotoxic stress, ischemia-reperfusion injury, and necrotic cell death. The intersection of PARP activity and NAD+ homeostasis is thus a major research area, with PARP inhibition and NAD+ replenishment studied as complementary approaches to NAD+ pool preservation in relevant model systems.

Research into PARP1-NAD+ biology typically uses NAD+ supplementation in conjunction with genotoxic stressors (e.g., hydrogen peroxide, UV irradiation, alkylating agents) to study how NAD+ pool dynamics influence cell fate outcomes (survival vs. necrosis), PAR chain formation kinetics, and downstream parthanatos signaling.

NAD+ and CD38: The NAD+ Hydrolase Problem

CD38 is a multifunctional ectoenzyme and NAD+ glycohydrolase that catalyzes the hydrolysis of NAD+ to ADP-ribose and nicotinamide (or the formation of cyclic ADP-ribose, cADPR, a calcium-mobilizing second messenger). CD38 is expressed on immune cells, vascular smooth muscle, and numerous other cell types, and its expression increases with age in multiple tissues.

Research has established CD38 as a major determinant of tissue NAD+ levels, particularly in aging: increased CD38 expression with age is documented to accelerate NAD+ turnover and reduce steady-state NAD+ concentrations, with downstream effects on sirtuin activity and mitochondrial function. The CD38-NAD+-sirtuin axis is an active area of investigation using both CD38 inhibitors (e.g., apigenin, 78c) and NAD+ precursor supplementation strategies in cell culture and animal aging models.

For researchers studying CD38-mediated NAD+ catabolism, exogenous NAD+ supplementation in cell culture allows manipulation of NAD+ availability independently of biosynthetic pathway interventions, providing a direct tool for dissecting the CD38-NAD+ interaction.

NAD+ Biosynthesis Pathways (Research Context)

Understanding NAD+ biosynthesis is essential for researchers designing supplementation experiments. Mammalian cells synthesize NAD+ through three main pathways:

• Salvage pathway (primary): Nicotinamide (Nam) → NMN (via NAMPT, the rate-limiting enzyme) → NAD+ (via NMNAT1/2/3). Also: NR → NMN (via NRK1/2) → NAD+.
• Preiss-Handler pathway: Nicotinic acid (NA) → NaMN → NaAD → NAD+ (via NAPRT, NMNAT, NADS).
• De novo synthesis: Tryptophan → kynurenine → quinolinic acid → NaMN → NAD+ (via IDO/TDO, ACMSD, QPRT).

Exogenous NAD+ supplementation bypasses all biosynthetic steps but requires cellular uptake. Research has investigated NAD+ uptake mechanisms, with evidence for extracellular CD73-mediated conversion to NMN (and further to nicotinamide riboside, NR) as one possible intracellular entry route, alongside direct uptake via connexin-43 hemichannels or other transporters in specific cell types. These uptake mechanisms are active areas of ongoing research.

Research Applications of NAD+

Sirtuin activity assays:

• In vitro SIRT1/SIRT3 deacetylase activity assays (fluorometric or HPLC-based) using NAD+ as co-substrate
• Dose-response characterization of NAD+ concentration dependence of sirtuin kinetics (Km determination)
• Substrate competition studies between sirtuins and PARPs for limiting NAD+ pools

Mitochondrial bioenergetics:

• NAD+/NADH ratio measurements (enzymatic cycling assay, or genetically encoded sensors such as SoNar or Frex) in cell lines under metabolic perturbation
• Seahorse XF respirometry in cells supplemented with exogenous NAD+ to examine effects on basal/maximal respiration, ATP production, and proton leak
• Mitochondrial biogenesis markers (PGC-1α, TFAM, citrate synthase activity) following NAD+ supplementation

DNA damage response:

• PARP1 activation kinetics (PAR immunoblot or PAR ELISA) under genotoxic stress with controlled NAD+ availability
• NAD+ depletion dynamics following oxidative or genotoxic insult (NAD+ quantitation by enzymatic cycling or LC-MS/MS)
• Rescue of PARP hyperactivation-mediated NAD+ depletion by exogenous NAD+ supplementation in necrosis vs. apoptosis models

Aging model research:

• Measurement of NAD+ levels in aged vs. young cell cultures or tissue preparations
• NAD+ supplementation effects on age-associated sirtuin activity decline in primary cells from aged donors
• CD38 inhibitor + NAD+ combination studies to dissect the relative contributions of biosynthesis decline vs. CD38-mediated catabolism to age-related NAD+ decline

Specifications

Parameter	Detail
Full name	Nicotinamide Adenine Dinucleotide (oxidized form, NAD+)
CAS Number	53-84-9
Molecular formula	C₂₁H₂₇N₇O₁₄P₂
Molecular weight	663.43 Da
Purity	≥99% by HPLC
Form	Lyophilized powder
Packaging	1000mg × 10 vials (10g total)
Storage	-20°C, desiccated, protected from light; moisture-sensitive
Stability notes	NAD+ is hygroscopic; avoid repeated freeze-thaw; prepare solutions fresh or store reconstituted aliquots at -80°C
Documentation	COA per lot (HPLC, MS identity, endotoxin per USP <85>); SDS available (US OSHA, EU REACH/CLP, BR FISPQ)

Handling Notes for Research Use

NAD+ is hygroscopic (absorbs moisture from air) and will degrade to NADH or ADP-ribose under aqueous conditions over time. Best practices for research use:

• Weigh and dissolve NAD+ under dry conditions; use pre-dried spatulas and containers
• Prepare stock solutions in cold, sterile, deionized water or appropriate buffer (pH 6–8; NAD+ is stable at neutral pH, less stable at extremes)
• Prepare working aliquots from stock; freeze at -80°C for extended storage
• Verify NAD+ integrity before critical experiments by measuring A₂₆₀/A₃₄₀ ratio — NADH absorbs at 340 nm, NAD+ does not; a rising A₃₄₀ indicates reduction/degradation
• Use within established stability windows — document preparation date and concentration on all aliquots

For Research Use Only. Not for human or veterinary use. NAD+ supplied by Glunova Biotech LLC has not been evaluated by the FDA or any regulatory agency for safety or efficacy in humans or animals and is intended solely for qualified preclinical laboratory research.